World journal of gastrointestinal pathophysiology · 2021
Cholangiocarcinoma and liver transplantation: What we know so far?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Safarpour Ali Reza, Askari Hassan, Ejtehadi Farshid, Azarnezhad Asaad, Raeis-Abdollahi Ehsan, Tajbakhsh Amir, Abazari Mohammad Foad, Tarkesh Firoozeh, Shamsaeefar Alireza, Niknam Ramin, Sivandzadeh Gholam Reza, Lankarani Kamran Bagheri, Ejtehadi Fardad
Аннотация
Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.